NeuroSense taps machine learning to optimize PrimeC Phase 3 testing
NeuroSense Therapeutics is collaborating with PhaseV for insights into how to better design the protocol for the planned…
Articles by Margarida Maia, PhD
Tambourine awards $5M to eight research projects into ALS
The Tambourine ALS Breakthrough Research Fund has committed more than $5 million in funding to eight research projects aiming to…
ALS women live longer than men despite faster functional decline
While women with amyotrophic lateral sclerosis (ALS) see a faster functional decline, men have shorter survival times, mostly due…
Certain spinal fluid biomarkers may predict responses to NurOwn
Treatment with NurOwn (debamestrocel), which BrainStorm Cell Therapeutics is developing for amyotrophic lateral sclerosis (ALS), may bring about changes in…
ALS Society-Brain Canada grant aids work into protein clumping in ALS
Researchers at the University of Waterloo will use a CA$125,000 (about $93,000) grant from the ALS Society of Canada…
Dewpoint wins grant to develop its condensate-modifying therapies
Dewpoint Therapeutics has received a grant from the Target ALS Foundation to advance the development of small molecules…
Edaravone formulation FAB122 fails to slow ALS progression
Note: This story was updated Jan 24, 2024, to correct that Radicava and Radicava Oral Suspension are available in Switzerland…
Stem cell-based therapy deemed safe in Phase 2 study
CL2020, a stem cell-based therapy that was being developed by the Life Science Institute, part of Mitsubishi Chemical, was…
Five toxic chemicals in air may raise, by 3 to 6 times, risk of ALS
Exposure to certain toxic airborne chemicals used in industry significantly increases — by up to six times — the odds…
Transcranial stimulation seen to boost muscle strength, life quality
Transcranial stimulation — a noninvasive technique that delivers low electrical currents to the brain to fine-tune nerve cell activity —…